{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
3,5-Diiodo-L-thyronine (3,5-T2), a potential metabolite of 3,3',5-triiodothyronine (T3), is an active thyroid hormone. It acts as an alternative ligand for thyroid hormone receptor beta. 3,5-Diiodo-L-thyronine has the capacity to stimulate hepatic lipid catabolism but acts by different from T3 molecular mechanisms to achieve this effect.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
BMS-794833 (N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-5-(4- fluorophenyl)-4-oxo-l,4-dihydropyridine-3-carboxamide) is an inhibitor of Met, VEGFR2, Ron, Axl and Flt-3 kinases. BMS-794833 demonstrated dose-dependent tumor
growth inhibition following oral administration in xenograft models. In cell culture, BMS-794833 inhibited
the proliferation of human tumor cell lines containing constitutively activated
Met receptor. BMS-794833 is an active moety of pro-drug BMS-817378. Bristol-Myers Squibb and Simcere Pharmaceutical Group are developing BMS-817378 for treatment of cancer.
![Structure of N-[(2E)-3-(3,4-Dihydroxyphenyl)-1-oxo-2-propen-1-yl]-D-tyrosine](/img/bf2f3d39-e4a7-4e29-8505-b039210ec75c.svg?size=200&context=xqtyjrfygb)
